Performance of P2x7 and P2Y Purinergic Receptors as an Inhibiting Factor in the Progression of Pulmonary Neoplastic Cells
Matheus Ribeiro Bizuti *
Federal University of Fronteira Sul, Chapecó, SC, Brazil.
Laura Nyland Jostl
Federal University of Fronteira Sul, Passo Fundo, RS, Brazil.
Emanuely Scramim
Federal University of Fronteira Sul, Chapecó, SC, Brazil
Keroli Eloiza Tessaro da Silva
Federal University of Fronteira Sul, Chapecó, SC, Brazil.
Luana Paula Schio
Federal University of Fronteira Sul, Chapecó, SC, Brazil.
Gabriela Vidotto Cavallieri
Environment and Regional Development at the University of Oeste Paulista, Presidente Prudente, SP, Brazil.
Renata Calciolari Rossi
University of Oeste Paulista, Presidente Prudente, SP, Brazil.
Débora Tavares de Resende e Silva
Program in Biomedical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil.
*Author to whom correspondence should be addressed.
Abstract
Different pathological processes are considered in lung cancer, such as nicotine deposition, oxidative stress, deregulation of metal ions and chronic inflammation. Purine signaling is involved in all processes, suggesting the importance of nucleotide receptors (P2X7 and P2Y) and adenosine receptors present in lung cells. The accumulation of toxic substances promotes chronic inflammation and cellular alteration, which induces the release of Adenosine Triphosphate (ATP) in the extracellular space, thus stimulating P2X7 receptors. The activation of P2X7 promotes an increase in the synthesis and release of some pro-inflammatory mediators. P2Y works by promoting the increase of intracellular calcium levels and, P2X7, changing cell permeability. Thus, drugs can be developed with a specific targeting for such recipients, thus provid additional therapeutic options to those existing.
Keywords: Adenosine triphosphate, cell proliferation, lung neoplasms, tobacco use disorder, purinergic signaling